Q2 2026 13F · SEC CIK 1799883
5AM Venture Management, LLC
Venture capitalFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $287.9M
- Reported positions
- 16
- Top holdings a year, 3 yrs
- +10.0%
- Assets under management
- $1.1B
5AM Venture Management, LLC is a venture capital that reported 16 positions worth $287.9M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Maplight Therapeutics Inc (MPLT, 11.8%), Tyra Biosciences Inc (TYRA, 11.4%), Entrada Therapeutics Inc (TRDA, 10.4%). A portfolio copying its top holdings returned 10.0% a year over the last 3 years, against 20.4% for the S&P 500.
5AM Venture Management, LLC holdings all 16 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| MPLTMaplight Therapeutics Inc | 11.8% | +0.0% | $34.0M |
| TYRATyra Biosciences Inc | 11.4% | +0.0% | $32.9M |
| TRDAEntrada Therapeutics Inc | 10.4% | +0.0% | $29.9M |
| PHVSPharvaris N V | 9.6% | +0.0% | $27.6M |
| CAMPCAMP4 Therapeutics Corporation | 8.9% | +0.0% | $25.6M |
| ARTVArtiva Biotherapeutics Inc | 7.9% | +0.0% | $22.8M |
| TECXTectonic Therapeutic Inc | 7.2% | +0.0% | $20.9M |
| ZNTLZentalis Pharmaceuticals Inc | 6.7% | +0.0% | $19.1M |
| CLDXCelldex Therapeutics Inc New | 6.4% | +0.0% | $18.5M |
| EYPTEyepoint Pharmaceuticals Inc | 5.2% | +0.0% | $15.0M |
| BHVNBiohaven Ltd | 3.8% | +0.0% | $11.0M |
| SRZNSurrozen Inc | 2.4% | -30.0% | $7.0M |
| SKYESkye Bioscience, Inc. | 2.3% | +0.0% | $6.7M |
| ALXOAlx Oncology Hldgs Inc | 2.2% | +0.0% | $6.3M |
| TARAProtara Therapeutics Inc | 1.8% | +0.0% | $5.2M |
| SLNSilence Therapeutics PLC | 1.8% | +0.0% | $5.2M |
What 5AM Venture Management, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
No new positions among the largest holdings.
Added to
No position grew by more than 5%.
Reduced
- SRZN Surrozen Inc-30.0% shares
Sold out
- ERAS Erasca Incwas 15.7%
- CNTA Centessa Pharmaceuticals PLCwas 6.4%
- GHRS Gh Research PLCwas 2.2%
- RLYB Rallybio Corpwas 0.7%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +80.4% /yr
- S&P 500 +20.1%
- 3 years
- +10.0% /yr
- S&P 500 +20.4%
- 5 years
- -1.6% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $287.9M | 16 |
| Q1 2026 | $360.2M | 20 |
| Q4 2025 | $318.1M | 21 |
| Q3 2025 | $273.0M | 25 |
| Q2 2025 | $260.1M | 29 |
| Q1 2025 | $264.4M | 31 |
| Q4 2024 | $419.1M | 31 |
| Q3 2024 | $484.0M | 28 |
| Q2 2024 | $447.1M | 28 |
| Q1 2024 | $446.6M | 26 |
| Q4 2023 | $377.0M | 25 |
| Q3 2023 | $347.5M | 26 |
Questions about 5AM Venture Management, LLC's portfolio
What stocks does 5AM Venture Management, LLC own?
5AM Venture Management, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 16 positions worth $287.9M. The largest are Maplight Therapeutics Inc (MPLT) at 11.8%, Tyra Biosciences Inc (TYRA) at 11.4%, Entrada Therapeutics Inc (TRDA) at 10.4%, Pharvaris N V (PHVS) at 9.6% and CAMP4 Therapeutics Corporation (CAMP) at 8.9%.
What did 5AM Venture Management, LLC buy last quarter?
5AM Venture Management, LLC opened no new positions and grew none by more than 5% among its largest holdings in Q2 2026.
What did 5AM Venture Management, LLC sell last quarter?
In Q2 2026, 5AM Venture Management, LLC sold all of Erasca Inc (ERAS), sold all of Centessa Pharmaceuticals PLC (CNTA), sold all of Gh Research PLC (GHRS), sold all of Rallybio Corp (RLYB) and Surrozen Inc (SRZN) (-30.0% shares), compared with its Q1 2026 filing.
How has 5AM Venture Management, LLC's portfolio performed?
A portfolio copying 5AM Venture Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +10.0% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +80.4% against +20.1%. Over 5 years: -1.6% a year against +11.6%.
When is 5AM Venture Management, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. 5AM Venture Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does 5AM Venture Management, LLC manage?
5AM Venture Management, LLC reported $1.1B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $287.9M.